Similar Papers

Paper Title
Journal
Date
Author
Abstract 2256: Low dose brain radiotherapy enhances the efficacy of an extracranial in situ vaccine regimen against melanoma brain metastases in a pre-clinical murine model
Raghava N Sriramaneni ... Zachary S Morris
Cancer Research | VOL. 80
Raghava N Sriramaneni, et. al.Raghava N Sriramaneni ... Zachary S Morris
13 Aug 2020
Abstract 4440: Bempegaldesleukin (NKTR-214), a CD122 preferential IL-2 pathway agonist, augments the in situ vaccine response to radiation of an extracranial tumor in a murine melanoma model, conferring response at non-radiated tumor sites in the brain
Paul A Clark ... Amber M Bates
Cancer Research | VOL. 80
Paul A Clark, et. al.Paul A Clark ... Amber M Bates
13 Aug 2020
Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
Paul A Clark ...
Radiation research | VOL. 195
Paul A Clark, et. al.Paul A Clark ...
07 Apr 2021
Abstract 1569: Role of NK and CD8+T cells in the antitumor effect elicited by combined treatment with radiation, tumor-specific antibody, and IL2 in a syngeneic murine model of head and neck squamous cell carcinoma
Wonjong Jin
Cancer Research | VOL. 81
Wonjong JinWonjong Jin
01 Jul 2021
View more papers

More From: Journal for immunotherapy of cancer

Paper Title
Journal
Date
Author
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Alessio Cortellini ... Biagio Ricciuti
Journal for ImmunoTherapy of Cancer | VOL. 13
Alessio Cortellini, et. al.Alessio Cortellini ... Biagio Ricciuti
04 Feb 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Cameron Wood ... Neal Ready
Journal for ImmunoTherapy of Cancer | VOL. 13
Cameron Wood, et. al.Cameron Wood ... Neal Ready
04 Feb 2025
Modulating lipid metabolism improves tumor immunotherapy
Yu Ping ... Yi Zhang
Journal for ImmunoTherapy of Cancer | VOL. 13
Yu Ping, et. al.Yu Ping ... Yi Zhang
04 Feb 2025
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Thomas Eigentler ... Ulrike Gnad-Vogt
Journal for ImmunoTherapy of Cancer | VOL. 13
Thomas Eigentler, et. al.Thomas Eigentler ... Ulrike Gnad-Vogt
04 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.